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Despite the high impact of mental disorders in society, European mental health
research is at a critical situation with a relatively low level of funding, and few
advances been achieved during the last decade. The development of coordinated
research policies and integrated research networks in mental health is lagging
behind other disciplines in Europe, resulting in lower degree of cooperation
and scientiﬁc impact.
To reduce more efﬁciently the burden of mental disorders in Europe, a con-
certed new research agenda is necessary. The ROAMER (Roadmap for Mental
Health Research in Europe) project, funded under the European Commission’s
Seventh Framework Programme, aims to develop a comprehensive and inte-
grated mental health research agenda within the perspective of the European
Union (EU) Horizon 2020 programme, with a translational goal, covering basic,
clinical and public health research.
ROAMER covers six major domains: infrastructures and capacity building,
biomedicine, psychological research and treatments, social and economic issues,
public health and well-being. Within each of them, state-of-the-art and
strength, weakness and gap analyses were conducted before building consensus
on future research priorities. The process is inclusive and participatory, incor-
porating a wide diversity of European expert researchers as well as the views
of service users, carers, professionals and policy and funding institutions.
Copyright © 2013 John Wiley & Sons, Ltd.Introduction
Europe has one of the highest levels of resourcing for mental
health in the world, with an overall good, though regionally
variable, supply of trained professionals, as well as coordi-
nated policies and systems to support their interventions
(WHO, 2005). Most importantly, policy-makers in the
European Union (EU) have acknowledged the tremendous
size and burden caused by mental disorders and mental
health problems in the EU and the need to respond in terms
of improved policy, strategies and resources at the EU level.
Starting with the 2005 European Commission (EC) Green
Paper (EC, 2005), through to the 2008 European Pact
on Mental Health and Well-being (EC and WHO Europe,
2008), and culminating in the European ParliamentInt. J. MethodResolution of 19 February 2009 on Mental Health, the focus
has been on a European strategy for mental health, while rec-
ognizing that much of the responsibility for implementation
of actions rests with Member States. This envisions a coordi-
nated and concerted response which needs to be proactive,
evidence-based, and directed to the design and implementa-
tion of comprehensive, integrated, effective and cost-efﬁcient
mental health systems, together with the societal and policy
changes needed to achieve the stated objectives. They should
address mental health promotion, prevention and early
targeted intervention, treatment and rehabilitation of mental
disorders, care and recovery and social inclusion across the
life span and for all societal groups.
Better understanding of the impact of mental disorders
has acted as a catalyst for action. Mental disorders accounts Psychiatr. Res. 23(Suppl. 1): 1–14 (2014). DOI: 10.1002/mpr
Copyright © 2013 John Wiley & Sons, Ltd.
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communicable diseases, with depression alone being the
largest component of Europe’s total burden (WHO,
2010). Estimates of the cumulative lifetime risk for mental
disorders suggest that up to the age 65, roughly 50% of the
EU population will be affected by mental disorders at
some point in their life (Wittchen et al., 2011). Enduring
mental health problems are also associated with economic
deprivation, poverty, stigma and social exclusion (MHE,
2007; Thornicroft et al., 2009; Brohan et al., 2011; Lasalvia
et al., 2013), employment problems, including absentee-
ism, and loss of productivity (McDaid et al., 2008).
Somatic co-morbidity and mortality are also higher in
individuals with mental disorders (Laursen et al., 2011;
De Hert et al., 2011). Moreover, results from epidemiologic
studies seem to indicate that the burden of mental disor-
ders is increasing more than decreasing (Murray et al.,
2012). The Global Burden of Disease Study 2010 estimated
that the proportion of Disability Adjusted Life Years
(DALY) caused by mental and behavioural disorders
increased from 5.38% in 1990 to 7.44% in 2010, a ﬁgure
similar to all neoplasms and higher than respiratory
diseases, musculoskeletal disorders and diabetes (Murray
et al., 2012).
Noteworthy, mental health is not merely the absence of
mental disorders, but a resource of importance for the
well-being of individuals, families and societies (Wahlbeck,
2011a). Population mental health and well-being have a
signiﬁcant impact on countries and their human, mental,
social and economic capital. The mental health of
Europeans is a crucial prerequisite for meeting the strategic
employment, education and social inclusion targets of
the EU.
Policies that aim to reduce the impact of mental disor-
ders in Europe will not be optimally effective if we do not
increase our knowledge of their determinants, on how to
prevent them, and on how to improve the efﬁcacy, effec-
tiveness and cost effectiveness of interventions and their
translation into clinical practice. Unfortunately, research
resources for mental health in many European countries
are relatively modest. For example, a study in Spain com-
paring the investment in research relative to DALY in the
population, found that mean funding per DALY was
€25.0 for all medical conditions, including mental
disorders, which is much higher than the research funding
devoted to speciﬁc mental disorders. For example, for
depression the mean funding per DALY was €4.0, alcohol
abuse €0.2, and bipolar disorder €2.9. Only schizophre-
nia (€35.8) exceeded the overall mean (Catalá López
et al., 2009). In another study, Chevreul et al. (2012)
compared public sector and not-for-proﬁt sources ofInt. J. Methods Psychiatr. Res. 23(Suppl. 1): 1–14 (2014). DOI: 10.1
Copyright © 2013 John Wiley & Sons, Ltd.research funds for the prevention and treatment of
mental health problems (excluding dementia) in France,
the United Kingdom (UK) and the United States.
Although the prevalence of mental health disorders is
roughly the same in those three countries, accounting for
17% to 25% of the overall burden of disease, and with
similar mental health expenditures per capita, the share
of health budget and charitable research funding devoted
to mental disorders ranged from 2% in France and 7%
in the UK to 16% in the United States. Per capita funding
also showed great variation ($1.1 in France, $3.5 in the UK
and $17.2 in the United States in 2007).
Private funds allocated to the development of new
treatments may also be decreasing in the area of psychiatry,
since major pharmaceutical companies have withdrawn
from key areas of neuroscience research. Deﬁciencies in
the science that underpins drug discovery, the costs associ-
ated with those advances, and regulatory difﬁculties have
also been reported as possible reasons for these decisions
(Nutt and Goodwin, 2011).
Not only are research resources comparatively small at
a national level, but there has been limited European coor-
dination of approaches to mental disorder and mental
health services research. The EU reports that research in
brain disorders is less funded and more fragmented than
in other areas when comparing research in the EU versus
United States (COM, 2008). This has resulted in (i) a lim-
ited research on the promotion of well-being, disorder
prevention and early intervention; (ii) the absence of a
clear route from basic discovery to potential preventive
and therapeutic applications that remains today long and
unpredictable until the point of a total lack of such a con-
tinuum; (iii) protracted and prohibitively expensive efforts
before novel biological and psychosocial treatments and
rehabilitation methods become available and are translated
in order to signiﬁcantly affect mental health burden on a
population level; and (iv) the absence of population-wide
strategies using cost-effective, and efﬁcient promotion
and preventive interventions across different developmen-
tal and life course stages and which promote social inclu-
sion and reduction of stigma and discrimination.
In this context, the ROAMER (roadmap for mental
health research in Europe) project, funded under the
EC’s Seventh Framework Programme (FP7), aims to
develop a comprehensive and integrated mental health
research roadmap, orientated to translational research,
sensitive to potential shifts in future needs in light of
demographic changes, aligned with the policies of the
Horizon 2020 programme, and addressing a pragmatic and
integrated approach to the development of a pan-European
strategy to matching mental health services to needs.002/mpr
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approach of ROAMER, putting this into the context of
current research gaps in mental health and mental disorder
research in the EU. We will illustrate this with examples
drawn from biomedical, psychological, well-being, social,
economic and public health perspectives.Methods
ROAMER aims at developing a roadmap on the promotion
and integration of mental health research across European
states. To ensure an effective and widely accepted roadmap,
we want the process to be inclusive and participatory,
incorporating a large diversity of research scientists from
many disciplines and also incorporating the view of service
users, carers, professionals, as well as policy and funding
institutions. The project started in October 2011 and is
taking place over three years.
Towards these goals ROAMER has established six
domains: (i) infra-structures and capacity building; (ii)
biomedicine; (iii) psychological research and interven-
tions; (iv) social and economic issues; (v) public health;Figure 1. Work plan strategy of the ROAMER project.
Int. J. Method
4(vi) well-being; and a cross-sectional task force on clinical
research (Figure 1). Within each of the domains, work
groups comprised of renowned scientists have been asked
to participate. Participants were selected based on their ex-
pertise and, importantly, complementarity. These groups
deﬁned the scope of each domain and the main issues to
be covered. They conducted an initial state-of-the-art
analysis of strength and weaknesses, enumerating core gaps
in current knowledge, and delineated advances needed in
research in their ﬁelds. This process was developed in three
different phases centred around face-to-face meetings.
Moreover, results were and will be presented to stake-
holders (service users, carers, professionals, government
and funding institutions, health service providers, and
others) in speciﬁc consensus meetings (Figure 2). A much
greater participation of scientists and stakeholders has been
achieved and will be further promoted through mail and
web-based surveys. A survey among national stakeholders’
associations about priorities for mental health research in
Europe has been already conducted (Fiorillo et al., 2013).
Documents are available on the ROAMER web page
(http://www.roamer-mh.org). Consensus in each of the
stages is being achieved using a modiﬁed Delphi method.s Psychiatr. Res. 23(Suppl. 1): 1–14 (2014). DOI: 10.1002/mpr
Copyright © 2013 John Wiley & Sons, Ltd.
Figure 2. General outline of the project.
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Current gaps
Classiﬁcation systems and biomedical research
Current diagnostic systems for mental disorders, such as
the International Classiﬁcation of Diseases, 10th revision
(ICD-10) and the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV/DSM-5), have facilitated
great advances, both in clinical and public health terms.
They have allowed the determination and comparison of
the frequency and impact of mental disorders across
countries, as well as the development of pharmacological
and psychosocial treatments for speciﬁc conditions, and,
importantly, facilitated the full consideration of mental
disorders among somatic conditions. Moreover, they
were also critical in the improvement of the detection of
mental disorders by health care services and in advances
in treatment adequacy. However, current classiﬁcation
systems have important limitations that may need to be
solved to achieve signiﬁcant further advances in under-
standing the aetiology and course of mental disorders,
and the development of improved diagnostic tools and
treatment strategies. To highlight such diagnostic
classiﬁcatory problems one can cite three interrelated
areas: comorbidity, biomarkers, genetic and optimized
pharmacologic and psychological treatment research.
Comorbidity describes the well-known phenomenon,
that most people with one somatic or mental disorder
are likely to also have other disorders, either concurrently
or consecutively (Kessler et al., 2011). Comorbidity is as-
sociated with increased health service use, lower response
to pharmacological and psychosocial interventions, and
an overall worse prognosis (Buitelaar, 2012). The meaning
and implications of comorbidity however remain unclear.
Comorbidity can be explained based on a number of
grounds. It could be simply an artefact of our current im-
perfect classiﬁcation systems, it can mean that one disor-
der causes another disorder, or that one disorder is a risk
factor for another or originate from disorders representing
different stages or developments of an underlying condi-
tion or liability factor (Krueger and Markon, 2006). For
example, prospective studies have located ﬁrst onset of
anxiety disorders typically in early childhood and adoles-
cence (Beesdo et al., 2009), and found that a substantial
proportion of individuals with early and primary anxiety
disorders later on develop secondary affective, substance
and also somatic disorders (Goodwin et al., 2002;
Zimmermann et al., 2003; Sareen et al., 2005; Mathew
et al., 2011). However, the research evidence for this ﬁnd-
ing and alternative models is limited and the knowledgeInt. J. Method
6about the meaning and implications in terms of diagnostic
and treatment decisions, as well as the pathogenic mecha-
nism behind such patterns remain unclear (Fava et al., 2014).
Further and similar research needs are evident with
regard to the high rates of comorbidity between mental
disorders and somatic disorders, such as depression and
diabetes or cardiovascular disease (CVD). This pattern is
associated with higher mortality (Fleischhacker et al.,
2008), lower rates of access to mental health care, poorer
response to treatment, and diagnostic difﬁculties such as
the interpretation of symptoms such as fatigue, sleeping
problems, loss of appetite, etc., that might be attributable
to the somatic condition and/or the mental disorder
(Van der Feltz-Cornelis et al., 2010). Comorbidity is also
associated with increased costs of care for managing
somatic health problems and their complications
(Molosankwe et al., 2012; Naylor et al., 2012). All these
issues present further challenges to classiﬁcation systems,
but might also have signiﬁcant implications for improved
research into aetiological mechanisms (like shared or
overlapping pathogenic mechanisms), the development
of adequate treatment models, and, consequently, appro-
priate organization of health care services.
Imperfect diagnostic classiﬁcatory systems might also
be co-responsible for the recent failure to develop more
potent and effective psychopharmacological treatments
and powerful biomarkers. After the tremendous progress
that has been made in pharmacotherapy of mental disor-
ders in the 1980s and 1990s, there has recently been a
marked decline in the development of new effective and
well tolerated medications. Because many drug candidates
fail to make the translational hurdle to clinical application,
there have been claims that this might be due to imperfect
diagnostic conventions. Similarly, a vast amount of re-
sources has been devoted during the last decade to ﬁnding
biomarkers that could serve diagnostic markers more reli-
ably and validly than our current problematic behavioural
or subjective psychopathological markers. Genetic re-
search has identiﬁed hundreds of genetic variations and
novel genes associated with major mental disorders, in-
cluding schizophrenia (Craddock et al., 2009), depression
(Shyn and Hamilton, 2010), autism (The Autism Genome
Project Consortium, 2007) and addiction (Wong and
Schumann, 2008). Moreover, several biochemical ﬁndings
have been reported to be related to either the presence or
severity of schizophrenia, depression and bipolar disorder.
However, frequently these ﬁndings have not been repli-
cated in similar studies (Kapur et al., 2012), and even
when replicated they have been shown to be unspeciﬁc
for a number of disorders. Similar problems are observed
in studies on the familiar aggregation, when examinings Psychiatr. Res. 23(Suppl. 1): 1–14 (2014). DOI: 10.1002/mpr
Copyright © 2013 John Wiley & Sons, Ltd.
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ders. These studies have focused on the concordance for
speciﬁc mental disorders (Kendler et al., 1994; McGufﬁn
et al., 1995; Hirshfeld-Becker et al., 2012). However, we
now know that some of these ﬁndings are unspeciﬁc and
that parental mental disorders confer increased risk not
only of concordant disorders but also for apparently
unrelated mental disorders among offspring (Dean et al.,
2010; McLaughlin et al., 2012).
The limitations of our current classiﬁcation systems
and the lack of success in detecting biomarkers have im-
portant implications for the delivery of the most appropri-
ate care to people with mental disorders. Despite the
advancements in some areas of medicine, personalized
medicine (Langreth and Waldholz, 1999) is not
progressing in psychiatry. “Stratiﬁed medicine”, the iden-
tiﬁcation of biomarkers or cognitive tests that stratify a
broad-illness phenotype into a ﬁnite number of treat-
ment-relevant subgroups has been proposed as an alterna-
tive to personalized medicine in psychiatry. However, it is
hard to envisage large-scale application of these proposals
until the earlier mentioned problems with classiﬁcation
systems are resolved (Kapur et al., 2012). For further dis-
cussions on biomedical issues relevant for mental health
research, see Schumann et al. (2013).Psychological research and treatments
Many of the problems listed earlier for biomedical re-
search also apply to psychological interventions (see
Wittchen et al., 2014). The effectiveness of various types
of empirically supported psychological treatments and in-
terventions such as cognitive behavioural therapy (CBT),
interpersonal therapy (IPT), as well as Problem Solving
Treatment (PST), Behavioural Analysis System of Psycho-
therapy (CBASP) and Mindfulness based cognitive therapy
is well established in hundreds of randomized clinical tri-
als and numerous reviews, particularly in areas like anxi-
ety, depressive, somatoform, and eating disorders, where
such methods are typically regarded as ﬁrst-line treat-
ments (Arch and Craske, 2009; Jakobsen et al., 2011;
Fjorback et al., 2011). Psychological therapies are also
established as core elements in the treatment of substance
use and most neurodevelopmental disorders and condi-
tions [e.g. attention deﬁcit hyperactivity disorder
(ADHD); Rader et al., 2009]. For the group of classic psy-
chodynamic and psychoanalytic methods similar strong
evidence is generally lacking. Just recently, critical and
empirically sound evaluation has been performed, provid-
ing evidence that these treatments are superior to non-
treatment conditions, but not exceeding the effect sizesInt. J. Methods Psychiatr. Res. 23(Suppl. 1): 1–14 (2014). DOI: 10.1
Copyright © 2013 John Wiley & Sons, Ltd.and related methodological quality of studies on the effec-
tiveness of CBT (Driessen et al., 2010; de Maat et al., 2009;
Smit et al., 2012; Town et al., 2011; Leichsenring and
Rabung, 2011; Gerber et al., 2011).
However, there is still a general lack of understanding
why these treatments are effective, as well as more gener-
ally about the basic mechanisms of behaviour (in terms
of initiation, maintenance and change). The critical trajec-
tories and determinants from functional and adaptive-
normal to dysfunctional abnormal states and conditions,
as well as the moderators and mediators of treatment-
related interventions remain under-researched and unclear.
Actually, although highly effective and despite some prog-
ress in clinical psychological research, little is known about
the active ingredients and related mechanisms of action of
evidence based psychotherapies. Further, we still do not
know whether mechanisms governing these aspects of be-
haviour change are the same or different across groups of
mental disorders, and whether individual genetic variation
or different individual capacities (such as “self-regulation”)
could play a role.
Finally, there is a fundamental lack of knowledge on
the state of research for psychological treatments and in-
terventions in Europe in terms of personnel and ﬁnancial
research capacity, infrastructures, translation into clinical
practice as well as dissemination and evaluation of out-
comes on the individual and societal level. In fact, there
is even a general lack of information about the degree to
which psychological treatments are applied in EU coun-
tries, where and what kinds of research and service delivery
programmes are in place, and how they are integrated into
the wider network of mental health care infrastructure. As
a result of this situation, Europe lacks even the most basic
prerequisites for an evidence-based clinical research policy
for psychological treatments and interventions.Social and economic impacts of well-being and mental
disorders
It is clear from our current understanding that the social
and economic consequences of poor mental health across
the life course can be profound. Many of these impacts fall
outside health care systems. Participation rates in employ-
ment for people with mental health needs are much lower
than for the general population, and much lower than for
people with severe physical health problems (Levinson
et al., 2010). Moreover, poor mental health in childhood
can have consequences through the life-course, with
reduced rates of participation in higher education, lower
rates of employment and lower levels of income for those
who are employed, and increased risk of contact with002/mpr
7
ROAMER: roadmap for mental health research Haro et al.criminal justice systems (Scott et al., 2001, Colman et al.,
2009). In contrast, positive well-being in childhood may
have long-term social and economic beneﬁts in adulthood
(Richards and Huppert, 2011).
While methods have been developed to help quantify
the costs of poor mental health, many of the associated
economic consequences of poor mental health remain
unclear. For instance, remarkably little research has been
undertaken in Europe to quantify the economic impacts
of comorbid mental and somatic health problems, even
though a number of studies looking at these issues in other
parts of the world have been published (Molosankwe et al.,
2012). Moreover, little is known about the economic ben-
eﬁts of better mental well-being.
While some studies have looked at the economic bene-
ﬁts of actions to protect and promote mental health, par-
ticularly with regard to actions targeted at children and
adolescents (Knapp et al., 2011; Mihalopoulos et al.,
2011; McDaid and Park, 2011), major gaps remain in
our knowledge. For instance, although the impact of
work-related stress and poor mental health on perfor-
mance at work and rates of absenteeism have been de-
scribed, studies looking at the effectiveness and economic
beneﬁts of actions both to prevent mental health problems
in work and to help individuals return to work more
quickly when they occur remain limited (McDaid and
Park, 2011; Nieuwenhuijsen et al., 2008). In terms of
treatment and support within the health care system,
cost-effectiveness studies have focused on pharmacother-
apies with much less attention given to comparison with
psychological and other interventions. New modes for
interventions, such as the use of the Internet and home-
based interventions also merit much more careful eco-
nomic analysis (Smit et al., 2011).
Another fundamental societal challenge related to
mental illness is the social exclusion experienced by people
with mental health problems. One key driver of social ex-
clusion is public stigma (Evans-Lacko et al., 2012), which
is derived from (i) problems of knowledge (ignorance or
misinformation); (ii) problems of attitudes (prejudice);
and (iii) problems of behaviour (discrimination). Evi-
dence in support of national anti-stigma interventions is
emerging in Europe (Smit et al., 2011); however, the impact
and costs of social exclusion are under-researched, as are
the mechanisms for reducing stigma and misinformation,
which is the primary cause of discrimination. Moreover,
given the importance of employment as a key element in
the recovery process for the majority of people with mental
health problems, careful analyses not only of interventions
to job activation and integration in work, but also of the role
played by social welfare and legal systems in providingInt. J. Method
8incentives and safeguards to encourage inclusion in work are
also required. Too little is known about these mechanisms
and any necessary viable solutions that are fair to all
Europeans.Public health and health services research
Public mental health aims at promoting health and preventing
ill-health at a population level through policies and large-scale
interventions. Public health clearly beneﬁts frommultinational
research. Policies, health systems and population level mental
health promotion and prevention interventions show great
diversity across European countries with very little knowl-
edge on how different structures and practices impact on
the mental health of European citizens. Decisions are
mostly based on political or social forces, and evidence is
lacking to back many of them. Public mental health actions
need to be better underpinned by valid research on the dis-
tribution of mental health and the magnitude of mental
disorders in the population, as well as research on effective
interventions to promote mental health, prevent mental
health problems and improve mental health service provi-
sion. Therefore, there is a great need for a coordinated re-
search action plan to gather the information required to
establish an evidence base for national mental health poli-
cies and an EU mental health strategy, and to disseminate
ﬁndings across the scientiﬁc community, to policy and
funding institutions as well as to service users, carers, and
professionals. This includes the comprehensive assessment
of the quality of mental health care services, in general
health care services such as primary and general hospital
care as well as specialist mental health care, and identifying
regional and cultural differences in Europe, based on valid
and comparable mental health services data (Höschl, 2009;
Wahlbeck, 2011b). Key topics in mental health services
research relate to service delivery, the mental health work-
force, novel health technologies, as well as the relationship
between users and professional carers, and issues around
governance and accountability. Development of evidence-
based initiatives to promote mental health and to prevent
mental health problems is a key aim of public health re-
search. On the policy level, research is needed to systemat-
ically evaluate population-level natural experiments, such
as shifts in mental health policies or in policies regarding
determinants of mental health.
While translational research has been developed to
some extent between basic science and clinical research,
the link between basic and public health researchers is
even weaker. Besides genetic epidemiology, there is still a
long way to go to take advantage of the collaboration of
basic, clinical and public health researchers. Long-terms Psychiatr. Res. 23(Suppl. 1): 1–14 (2014). DOI: 10.1002/mpr
Copyright © 2013 John Wiley & Sons, Ltd.
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terminants of mental health and mental disorders. In this
sense, the goal of the ROAMER project is to build bridges
so that real translational research can be promoted. As an
example, we may need to develop alternative databases to
the current psychiatric diagnostic systems, which strongly
encourage use of novel and alternative approaches to phe-
notypes of mental health.
Mental health services need to change their relationship
with patients. Research to develop novel incentives for pa-
tient-centred services and to deﬁne appropriate perfor-
mance indicators is crucial to support the development
of purchaser–provider models for mental health. The
expert patient role, patient empowerment, as in shared
decision-making, and service evaluation needs to be better
researched by mixed methods and service user-led research
approaches.
Opportunities created by better research use of rou-
tinely collected health care data and access to novel types
of data from electronic patient records such as routine out-
come monitoring and patient centred outcome research
will be acknowledged in the roadmap, and the inclusion
of service users in initiation, design, implementation
and evaluation of mental health services research will be a
core issue.Well-being
Well-being is an emergent social and political priority in
Europe. Well-being reﬂects individuals’ perception and
evaluation of their own lives in terms of their affective
states, psychological and social functioning (Keyes and
Lopez, 2002). There are different components of well-
being. Experienced well-being can be measured with in-
struments such as the Experience Sampling Method
(Csikszentmihalyi and Larson, 1987) and the Day Recon-
struction Method (Kahneman et al., 2004). Evaluative
well-being captures judgments of overall life satisfaction
or fulﬁlment on distinct domains of personal functioning,
such as autonomy, personal growth and achievement of
life purposes. Current research across Europe into these
two approaches offers different perspectives. Preliminary
work suggests that different aspects of well-being may have
distinct physiological correlates. Measures of subjective
well-being also correlate highly with personality measures,
such as neuroticism and extraversion, suggesting that well-
being may be a stable trait. However, longitudinal studies
indicate only moderate stability of life satisfaction over
time, suggesting that there are potentially modiﬁable envi-
ronmental factors that may have an impact on subjective
well-being.Int. J. Methods Psychiatr. Res. 23(Suppl. 1): 1–14 (2014). DOI: 10.1
Copyright © 2013 John Wiley & Sons, Ltd.From a health perspective, the concept and measure-
ment of well-being goes beyond the mere presence or ab-
sence of illness or disability. Well-being also incorporates
the impact of positive health and functioning that has
typically received little attention in health sciences. From
both a policy and a health perspective, well-being at any
stage in life is an important outcome in and of itself. How-
ever, despite the fact that measures of well-being could
provide an important source of information for compara-
tive effectiveness analyses of behavioural and biomedical
interventions, they are currently not included in many in-
tervention trials, probably also because of the many and
sometimes diverging facets associated with the term and
concept of well-being.
Aspects of subjective well-being have been associated
with changes in life expectancy, as well as disease risk,
mortality and disability. However the evidence deﬁnitively
linking well-being to speciﬁc health and economic out-
comes at the population level is limited. In contrast to
our knowledge about trends in, e.g. physical disability dur-
ing old age, we know little about population and cohort
trends in well-being over time. At the individual level,
there is a growing body of evidence for a distinct role of
positive affect and life evaluations in predicting important
health outcomes. Several lines of research suggest that pos-
itive psychological states, including both experienced pos-
itive emotions and evaluative components of well-being,
may play important roles in motivating behaviour change,
in buffering against suffering associated with illness and its
symptoms and in speeding recovery or preventing disease,
whereas negative states may have the opposite effects.
However, much of this work has been informed by global
assessments of positive or negative affect averaged over
time, apart from measures of time use or context.Research infrastructure, training and funding
Besides the themes addressed earlier, three transversal ele-
ments are necessary to promote and advance mental
health research in Europe: research infrastructures, train-
ing and funding.
When compared to other ﬁelds of health research, it is
acknowledged that there is a lack of research units and
transversal infrastructures (shared databases, cohorts,
technical platforms, etc.) that can be either speciﬁc to
mental health or generic but useable for mental health re-
search (Thornicroft et al., 2002; Ayuso-Mateos et al.,
2011). Furthermore, existing entities and infrastructures
suffer from a lack of visibility so that many researchers
are not aware of their presence. Therefore, research activ-
ity in mental health could be greatly enhanced by better002/mpr
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infrastructures, as well as more awareness of related research
units that could constellate to form research networks. This
raises the question of the need for a body in charge of steering
such communication and coordinating activities and, further-
more, performing knowledge brokering and thus bridging
the current gap between research and decision-making.
In terms of research training, there is a lack of dedi-
cated programmes across Europe. This reﬂects insufﬁcient
investment in this area. A large share of existing programmes
are offered in the UK which is, besides ﬁnancial and social
reasons, one of the factors in part explaining the “brain
drain”, i.e. the migration of researchers from “Eastern” to
“Western” Europe.
Finally sustainable and sufﬁcient funding of mental
health research is important, although as noted earlier, this
is by far not the only factor required for progress. Most
importantly, funders need to realize that there is a relative
under-funding of mental health research in many coun-
tries relative to the potentially avoidable health and
economic burden of mental disorders (Chevreul et al.,
2012), while resources allocated to this area have been pre-
viously estimated to yield a high return on investment
(Health Economics Research Group et al., 2008).Conclusions
In Europe, research in mental health and mental disorders
is currently at a critical stage. Signiﬁcant advances in
knowledge have not been achieved during the last decade.
For example, few new treatments have appeared and the
search for biologicalmarkers has provided inconsistent results
despite substantial efforts. Insufﬁcient and uncoordinated
communication between disciplines often results in a
fragmented approach to mental health research, with a risk
of dilution of its components in broader disciplines such as
psychology, neuroscience, genetics, and public health. As a
result, the development of coordinated research policies
and integrated research networks in mental health is lag-
ging behind other disciplines, resulting in a lower degree
of cooperation between and within disciplines, and in a
lower impact of its scientiﬁc output. Given the impact of
mental disorders in society, the relatively low level of
funding in research and the lack of a consistent European
policy, a roadmap for mental health research is absolutely
necessary. Against a background of limited resources for
research, one key issue will be how to prioritize areas of
research. Should this be done on the basis of burden of
disease, on whether there are areas of “low hanging fruit”
which might deliver early gains, on the priorities of suf-
ferers and carers, or other criteria? Most likely, prioritiesInt. J. Method
10will be based on a combination of factors. It is important
to acknowledge too that Europe has special strengths
which can play to in research: case registers and socialized
healthcare systems enable epidemiological, genetic, eco-
nomic and outcomes research; global telecommunication
industries and a web-literate population will support
research into new models of remote and e-health care;
and a history of patient and carer involvement which
encourages participatory research.
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